ABSTRACT BACKGROUND Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help
D ilated cardiomyopathy (DCM) affects up to
w1 in 250 individuals (1) and is the leading global cause of heart transplantation (2,3).
Despite improvements in pharmacological and device-based therapy, clinical outcomes in DCM remain poor, with a 20% 5-year mortality rate (4, 5) .
As such, there is a pressing need for better mechanistic understanding, improved risk stratification, and identification of novel therapeutic targets for DCM.
Recently, truncating variants in the gene for the sarcomeric protein titin (TTNtv) have been identified as the largest single genetic cause of DCM, found in 10% to 20% of cases (6, 7) . However, their phenotypic and clinical significance remains unclear, as the presence and extent of phenotypic and outcome differences in DCM patients with and without TTNtv varies between studies (6-9).
Our aim in this study was to define the genotype- family member up to third-degree relative) (12) was recorded. A history of atrial or ventricular arrhythmia prior to enrollment was documented as previously described (13) . Conduction disease was recorded in the presence of any degree of heart block.
CARDIAC MAGNETIC RESONANCE. All patients underwent CMR at 1.5-T (Siemens Sonata or Avanto scanners, Siemens Medical Systems, Erlangen, Germany). Breath-hold steady-state free precession cine images were acquired in 3 long-axis planes and shortaxis slices as previously described (5) . LGE images were acquired using a breath-hold inversion recovery sequence following administration of 0.1 mmol/kg of gadolinium contrast agent (Magnevist or Gadovist, Bayer, Leverkusen, Germany) as previously described (5) . Left ventricular (LV) volumes, function, and mass were measured using a semiautomated thresholdbased technique (CMRtools, Cardiovascular Imaging Solutions, London, United Kingdom). Maximum left atrial (LA) volumes were assessed from the 2-and 4-chamber views at ventricular end-systole (14) . All volume and mass measurements were indexed to body surface area and referenced to age-and sex-based tables (10) . All CMR measurements were performed by operators blinded to genetic and outcome data. (17) , and are described in detail in
Online Table 2 .
FOLLOW-UP DATA COLLECTION AND ADJUDICA-TION. Follow-up data was collected from primary and hospital care records and patient questionnaires.
Survival status was also identified using the U.K.
Health and Social Care Information Service to ensure that no deaths were missed. Death certificates and post-mortem reports were obtained where applicable.
All primary endpoint events were adjudicated by an independent committee of 3 senior cardiologists Table 3 .
Imaging characteristics of the DCM cohort are shown in Online Figure 1 and Online Table 1 .
Genotype, Phenotype, and Outcome Study of Titin DCM patients-mainly localized in the septum (n ¼ 188; 75.2%) (Online Table 4 ).
CURATION OF TITIN TRUNCATING VARIANTS.
TTNtv in constitutively expressed cardiac exons were found in 83 patients (11.6%). The variants are listed in Online Table 5 . The position of the TTNtv and protein domains is shown in Figure 1 . Tayal et al. Tables 6 and 7) . Genotype, Phenotype, and Outcome Study of Titin DCM secondary arrhythmic and heart failure endpoints and cardiovascular mortality (Online Figure 2 ). We did, however, find that TTNtv DCM is associated is an evolutionary conserved kinase that can modulate cardiac hypertrophy (22) , and increased mTORC1
signaling is an adaptive response to cardiac stress in rat models. We have recently shown that rats with TTNtv had elevated mTORC1 signaling at baseline but were not able to increase signaling when stressed (23) . This may offer a biological explanation for the blunted hypertrophic response observed in human TTNtv DCM, although the mechanistic link between TTNtv and mTORC activation remains to be established.
PREVALENCE OF TTNtv IN DCM.
The prevalence of TTNtv in this cohort (w12%) is lower than in previous studies, which showed a prevalence of up to 25% in familial DCM cases (7). However, TTNtv frequency ranged from w8% to 40% across the 3 clinical cohorts in the study by Herman et al. (7), with the highest frequencies observed in patients evaluated for cardiac Tayal et al.
transplantation or with severely impaired function.
Therefore, it is plausible that TTNtv are enriched in severe/end-stage DCM cohorts, and the prevalence of w12% that we observe is a more accurate reflection of the frequency of TTNtv in an unselected and ambulant DCM population. This is supported by the 14% frequency of TTNtv observed in an independent cohort of DCM patients referred for clinical genetic testing (24) . 
CONCLUSIONS
In this study, we identified distinct cardiac endophenotypes of TTNtv DCM that may offer mechanistic insights into the pathogenesis of DCM. We also found that the clinical outcome in TTNtv DCM is similar to patients without TTNtv DCM in a cohort of patients with mild to moderate disease.
We note that the prevalence of TTNtv in severe disease in transplant-listed cases can be as high as 20%, almost double that in the current study, which remains unexplained. In summary, although TTNtv are common in DCM and may be used to confirm a genetic cause for DCM and for cascade screening, they do not appear to predict clinical outcomes in ambulant DCM cases with medium-term (w4 year) Truncating variants in the titin gene (TTNtv) are the largest single genetic contributor to dilated cardiomyopathy (DCM). In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic indicators for all-cause DCM also predict outcomes in TTNtv DCM, and that TTNtv DCM does not appear to be associated with a substantially worse medium-term prognosis, despite patients presenting at a younger age.
CVS ¼ cardiovascular; MRI ¼ magnetic resonance imaging. 
